在晚期癌症的临床测序项目中，Wu等人（2013年，癌症发现）确定了许多不同癌症类型患者的FGFR融合。这些融合也被发现保持寡聚能力，并导致细胞增殖增强。含有这些融合的细胞株对帕佐帕尼有反应。另外，在一例肝内胆管癌患者中单独应用波那替尼和帕唑帕尼治疗并融合后，肿瘤体积减小。作者利用这些病例强调需要加强临床测序工作。
In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. Cell lines harboring these fusions were shown to respond to pazopanib. Additionally, tumor size reduction was achieved by both ponatinib and pazopanib treatments administered separately in a single patient with intrahepatic cholangiocarcinoma and this fusion. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.